remdesivir

IT for Change was among 150 signatories to an open letter led by Médecins Sans Frontières/Doctors Without Borders (MSF), urging Gilead Sciences to give up its exclusive rights on patents and regulatory and trial data in remdesivir. Monopoly-based patents regime in this could obstruct access to lifesaving treatment for Covid-19.

As the…